title: Bone alterations associated with HIV.
abstract: HIV infection and initiation of antiretroviral therapy (ART) have been consistently associated with decreased bone mineral density (BMD), with growing evidence linking HIV to an increased risk of fracture. This is especially concerning with the expanding number of older persons living with HIV. Interestingly, recent data suggest that HIV-infected children and youth fail to achieve peak BMD, possibly increasing their lifetime risk of fracture. Elucidating the causes of the bone changes in HIV-positive persons is challenging because of the multifactorial nature of bone disease in HIV, including contribution of the virus, immunosuppression, ART toxicity, and traditional osteoporosis risk factors, such as age, lower weight, tobacco, and alcohol use. Thus, practitioners must recognize the risk of low BMD and fractures and appropriately screen patients for osteoporosis if risk factors exist. If fractures do occur or elevated fracture risk is detected through screening, treatment with bisphosphonate medications appears safe and effective in the HIV+population.
authors: Division of Endocrinology, Metabolism and Diabetes, University of Alabama at Birmingham, FOT 702, 2000 6th Avenue South, Birmingham, AL, 35233-0271, USA, warriner@uab.edu.
authors: Amy H
authors: AH
authors: Warriner
authors: Michael
authors: M
authors: Mugavero
authors: E Turner
authors: ET
authors: Overton
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D002648:Child; D005260:Female; D050723:Fractures, Bone; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D010024:Osteoporosis; D012307:Risk Factors; D014807:Vitamin D
chemical_list: D019380:Anti-HIV Agents; D014807:Vitamin D